Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Overview

Save information for later
Sign Up

Learn About Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)

View Main Condition: Mucopolysaccharidoses (MPS)

What is the definition of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)?
Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is a rare metabolic condition in which the body is unable to break down long chains of sugar molecules called glycosaminoglycans. As a result, toxic levels of these sugars accumulate in cell structures called lysosomes, leading to the various signs and symptoms associated with the condition. These signs and symptoms may include abnormalities of the skeleton, eyes, heart and respiratory system. There are two forms of MPS IV. MPS IVA is caused by changes in the GALNS gene. MPS IVB is caused by genetic changes in the GLB1 gene. Both forms are inherited in an autosomal recessive manner.
What are the alternative names for Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)?
  • Mucopolysaccharidosis type IV
  • MPS4
  • MPSIV
  • Morquio disease
  • Mucopolysaccharidosis type 4
What are the different types of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)?
Who are the top Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Local Doctors?
Paul Harmatz
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Pediatric Gastroenterology
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Pediatric Gastroenterology

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
Languages Spoken:
English
Offers Telehealth

Paul Harmatz is a Pediatric Gastroenterologist in Oakland, California. Dr. Harmatz is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome). His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome), Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), and Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome).

Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Pediatric Orthopedics | Orthopedics
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Pediatric Orthopedics | Orthopedics
1600 Rockland Rd, Nemours Dupont Pediatrics, 
Wilmington, DE 
Languages Spoken:
English
Accepting New Patients

William Mackenzie is a Pediatric Orthopedics specialist and an Orthopedics provider in Wilmington, Delaware. Dr. Mackenzie is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome). His top areas of expertise are Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome), Brachydactyly Mononen Type, Achondroplasia, Osteotomy, and Spinal Fusion. Dr. Mackenzie is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Florence, IT 

Amelia Morrone practices in Florence, Italy. Ms. Morrone is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome). Her top areas of expertise are Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome), Brachydactyly Mononen Type, Mucopolysaccharidosis Type 4A (MPS IVA, Morquio Syndrome Type A), and PMM2-Congenital Disorder of Glycosylation.

What are the latest Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Clinical Trials?
Mucopolysaccharidosis Patients in France in the Era of Specific Therapeutics

Summary: The goal of this observational study is to characterize the epidemiology and natural history of MPS diseases by building a retrospective and prospective collection of extensive phenotypic data from French MPS patients.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Longitudinal Study of Neurodegenerative Disorders

Summary: The purpose of this study is to understand the course of rare genetic disorders that affect the brain. This data is being analyzed to gain a better understanding of the progression of the rare neurodegenerative disorders and the effects of interventions.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center